PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
1807413.38%
Cash & equivalents growing 1807413.38% while AGEN's declined -2.74%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
1807413.38%
Below half of AGEN's -2.74%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1991465.49%
Below half of AGEN's -6.49%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1993307.75%
Below half of AGEN's -3.14%. Michael Burry sees a potential red flag for stagnation or capital shortage.
9610300.00%
Less than half of AGEN's -25.98%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.78%
Less than half of AGEN's 889.23%. David Dodd sees a more disciplined short-term liability approach.
2.24%
Above 1.5x AGEN's 0.87%. Michael Burry suspects significant leverage additions. Check coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.24%
Above 1.5x AGEN's 1.28%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
3.56%
Above 1.5x AGEN's 1.69%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-1.35%
1.25-1.5x AGEN's -0.94%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of AGEN's 94.41%. David Dodd notes simpler yoy equity changes vs. competitor.
-3.71%
Below half AGEN's 22.33%. Michael Burry sees potential underperformance in building shareholder capital.
-100.00%
≥ 1.5x AGEN's -3.14%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
2.24%
Above 1.5x AGEN's 0.86%. Michael Burry sees a major jump. Investigate leverage rationale.
-3606.58%
Less than half of AGEN's 10.26%. David Dodd sees better deleveraging or stronger cash buildup than competitor.